{
     "PMID": "8782231",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "19961226",
     "LR": "20161123",
     "IS": "0969-8051 (Print) 0969-8051 (Linking)",
     "VI": "23",
     "IP": "3",
     "DP": "1996 Apr",
     "TI": "Pharmacological characterization and positron emission tomography evaluation of 4-[76Br]bromodexetimide and 4-[76Br]bromolevetimide for investigations of central muscarinic cholinergic receptors.",
     "PG": "235-43",
     "AB": "4-[76Br]bromodexetimide and its inactive enantiomer 4-[76Br]bromolevetimide were prepared via electrophilic bromodesilylation using chloramine-T and no-carrier-added (NCA) [76Br]NH4. In vitro, Bmax measured on rat cortex membranes were 3.7 +/- 0.2 and < 0.07 pmol/mg protein for 4-[76Br]bromodexetimide and 4-[76Br]bromolevetimide, respectively. The kD of 4-[76Br]bromodexetimide was 1.9 +/- 0.3 nM. In vivo studies in rats showed specific uptake of 4-[76Br]bromodexetimide in cortex, striatum, thalamus and hippocampus. No specific uptake was observed with 4-[76Br]bromolevetimide. With [76Br]bromodexetimide, positron emission tomography (PET) studies in primates demonstrated a preferential accumulation of the radioactivity in the cortex and striatum which was displaced to the level of cerebellum by dexetimide. With 4-[76Br]bromolevetimide, the radioactivity concentrations in the cortex and striatum were similar to that of cerebellum.",
     "FAU": [
          "Loc'h, C",
          "Kassiou, M",
          "Strijckmans, V",
          "Bottlaender, M",
          "Katsifis, A",
          "Schmid, L",
          "Maziere, M",
          "Lambrecht, R M",
          "Maziere, B"
     ],
     "AU": [
          "Loc'h C",
          "Kassiou M",
          "Strijckmans V",
          "Bottlaender M",
          "Katsifis A",
          "Schmid L",
          "Maziere M",
          "Lambrecht RM",
          "Maziere B"
     ],
     "AD": "Service Hospitalier Federic Joliot, Orsay, France.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "PL": "United States",
     "TA": "Nucl Med Biol",
     "JT": "Nuclear medicine and biology",
     "JID": "9304420",
     "RN": [
          "0 (Bromine Radioisotopes)",
          "0 (Muscarinic Antagonists)",
          "0 (Receptors, Muscarinic)",
          "162661-31-6 (4-bromodexetimide)",
          "43477QYX3D (Dexetimide)"
     ],
     "SB": "IM",
     "MH": [
          "Animals",
          "Autoradiography",
          "Brain/*diagnostic imaging/metabolism",
          "*Bromine Radioisotopes/pharmacokinetics",
          "Cell Membrane/metabolism",
          "Cerebral Cortex/diagnostic imaging/metabolism",
          "Dexetimide/*analogs & derivatives/chemical synthesis/pharmacokinetics",
          "Frontal Lobe/metabolism",
          "Isotope Labeling/methods",
          "Kinetics",
          "Male",
          "*Muscarinic Antagonists",
          "Radioligand Assay",
          "Rats",
          "Rats, Wistar",
          "Receptors, Muscarinic/*analysis/metabolism",
          "Tissue Distribution",
          "Tomography, Emission-Computed/*methods"
     ],
     "EDAT": "1996/04/01 00:00",
     "MHDA": "1996/04/01 00:01",
     "CRDT": [
          "1996/04/01 00:00"
     ],
     "PHST": [
          "1996/04/01 00:00 [pubmed]",
          "1996/04/01 00:01 [medline]",
          "1996/04/01 00:00 [entrez]"
     ],
     "AID": [
          "0969-8051(95)02052-7 [pii]"
     ],
     "PST": "ppublish",
     "SO": "Nucl Med Biol. 1996 Apr;23(3):235-43.",
     "term": "hippocampus"
}